World Journal of Biology Pharmacy and Health Sciences
eISSN: 2582-5542
Cross Ref DOI: 10.30574/wjbphs
Journal homepage: https://wjbphs.com/

(REVIEW ARTICLE)

Check for updates

Comprehensive review on advanced antipyretic and anti-nociceptic agents: Efficacy; safety and emerging therapies

Vidya Niwas, Sanjita Das * and Umar Ashfaque

Department of Pharmacy; SMAS; Galgotias University; Plot No. 02; Sector-17 A; Yamuna Expressway; Greater Noida; Uttar Pradesh;203201, India.

World Journal of Biology Pharmacy and Health Sciences; 2024, 20(02), 258–269

Publication history: Received on 10 September 2024; revised on 21 October 2024; accepted on 23 October 2024

Article DOI: https://doi.org/10.30574/wjbphs.2024.20.2.0816

Abstract

Fever; characterized by an increased core temperature; is a complex physiological reaction to illness involving acute-phase reactants and many physiological; endocrinological; and immunological systems. Antipyretics; chiefly non-steroidal anti-inflammatory Drugs (NSAIDs) and paracetamol; are essential for the management of fever and related discomfort. These medicines primarily function by inhibiting cyclooxygenase enzymes; so diminishing the production of prostaglandin E2 in the hypothalamus and subsequently decreasing the thermal set point. Although paracetamol is acknowledged for its safety when utilized correctly; it presents concerns of hepatic toxicity and overdose; requiring vigilant monitoring; especially in pediatric patients or those with concomitant conditions. Conversely; ibuprofen typically has greater antipyretic efficacy; particularly in pediatric populations; although its application may be constrained by gastrointestinal adverse effects and renal considerations. Recent breakthroughs in this domain concentrate on improving the safety and efficacy of antipyretic drugs; particularly for at-risk populations such as the elderly and children. Innovations like COX-2 selective inhibitors and advanced delivery technologies; including nanomedicine; offer exciting opportunities for enhancing pain management and fever therapy. Future study should emphasize the customization of therapy according to pharmacodynamics; possible drug interactions; and patient attributes to enhance therapeutic results. An interdisciplinary approach is crucial for the appropriate management of fever and pain; enhancing patient welfare and progressing clinical practices in antipyretic and antinociceptive therapies.

Keywords: Fever; Antipyretics; Antinociceptive NSAIDs; Acetaminophen; Pain management

1. Introduction

Fever is defined as "An elevated core temperature, frequently but not exclusively, constitutes a defensive response of multicellular organisms (hosts) to the invasion of living microorganisms or inanimate substances identified as pathogenic or foreign by the host." The complex physiological response to illness known as the febrile response, of which fever is only one aspect, entails the synthesis of acute-phase reactants, an elevation in core temperature regulated by cytokines, and the activation of many physiological, endocrinological, and immunological systems(1). Literally speaking, the term "antipyretic" describes pharmaceuticals that reduce fever without influencing normal or biologically raised body temperature. The body's thermoregulatory system typically maintains temperature within the temperature range of 36.2 - 37.5 °C through different intrinsic mechanisms. Pain is characterized as a sensation of physical or mental distress provoked by external stimuli. Pain can be classified into different types according to their characteristics: neuropathic pain, arising from pathology or abnormalities in the sensory nerve system; nociceptive discomfort, which may be sharp, aching, or throbbing and arises from tissue injury; and chronic pain, which endures for more than six months. Recent developments in the comprehension of various pain signaling pathways are contributing to an enhancement of analgesic strategies to mitigate different pathological processes (2). Transduction, conduction,

* Corresponding author: Sanjita Das

transmission, and perception are all components of nociceptive pain. The activation of nociceptors, which are specialized pain receptors with unmyelinated (C-fiber) or thinly myelinated (Aδ-fiber) axons, polymodal sensory fibers of primary sensory neurons located in the trigeminal and dorsal root ganglia, results in nociceptive signaling in physiological pain. During the transduction process, a dangerous thermal, mechanical, or chemical input is converted into electrical activity at the peripheral terminals of nociceptor sensory fibers. A few specific receptor ion channels that are only expressed by nociceptors help to assist this procedure(3). This promotes the preservation of thermal homeostasis by regulating the function of the Central Nervous System (CNS), which helps to avert potentially fatal situations (4,5). The body's natural antipyretic mechanism continues to develop during a fever, mostly by inhibiting the enzymes required to produce inflammatory mediators. This limits the intensity and duration of the fever. While fever and related reactions constitute our body's first line of defense, a persistent fever that lasts longer than expected is harmful. As a result, several pharmaceutical medications are released to treat illnesses linked to pyrogens and restore health. The majority of these antipyretics are classified as non-steroidal anti-inflammatory Drugs (NSAIDs)(6,7). Antipyresis can be produced pharmacologically or by physical means, such as by using an external cooling device to physically lower body temperature. Physical techniques include putting out the patient with cold water, sponging them with cool water, An electric fan that blasts cold air over them is another option or using a solution of alcohol and water. However, thermogenesis makes these methods comparatively ineffectual when used alone(6). For this reason, antipyretic medications like paracetamol are often given along with external cooling, particularly to children. However, the most common treatments for antipyresis are non-steroidal anti-inflammatory drugs (NSAIDs), like aspirin, or antipyretic analgesics, like paracetamol. The selective cyclooxygenase-2 (COX-2) inhibitor nimesulide is prescribed in certain nations (mostly for fevers in children). Despite being more selective on COX-2 than nimesulide, rovecoxib and etoricoxib are not as commonly used as antipyretics, despite having a well-established analgesic effect in arthritis (8) (Figure 1). Typically, pediatricians start antipyretic treatment when a child's temperature rises above 38.3C (101F) and when they feel more comfortable generally (8,9).

2. Mechanism of action of nonsteroidal anti-inflammatory drugs (NSAIDs)



Figure 1 Mechanism of action of NSAIDs

NSAIDs (nonsteroidal anti-inflammatory drugs) like ibuprofen and antipyretics like acetaminophen work primarily by blocking the activity of cyclooxygenase (COX) enzymes. This inhibition efficiently lowers the thermal set point and hence lowers fever by inhibiting prostaglandin E2 (PGE2) synthesis in the hypothalamus(10). For cyclooxygenase, COX-1 and COX-2 are the two isoenzymes. Besides keeping the kidneys working, helping platelets stick together, and protecting the lining of the digestive system, the body makes COX-1 all the time. The body does not make COX-2 on its own If there is an inflammatory reaction, it becomes active. NSAIDs are generally nonselective This indicates that they inhibit COX-1 and COX-2. However, NSAIDs that are specific to COX-2, such celecoxib, only function against COX-2, so they have additional negative effects. Most importantly, Since COX-1 is the primary molecule that maintains the integrity of the stomach mucosa and COX-2 is the primary molecule that causes inflammation, COX-2 selective NSAIDs should help

reduce inflammation without harming the gastric mucosa (11). NSAIDs can help treat severe gout pain because they stop urate crystals from entering in. They do this by blocking prostaglandin synthase(12). Some NSAIDs can help lower fevers, so they can be used to treat them(13). Elevated prostaglandin E2 (PGE2) levels produce fever by changing the pace at which the hypothalamic neurones that regulate thermoregulation activate(14). Antipyretics function by blocking the enzyme COX, which results in the hypothalamus' overall suppression of prostanoid production (PGE2) (10). The hypothalamus receives PGE2 signals that elevate the body's temperature setpoint (15). Studies have indicated that ibuprofen works better than paracetamol as an antipyretic. (acetaminophen) (16).

2.1. Mechanism of action of acetaminophen

The most widely used over-the-counter analgesics are antipyretics and paracetamol(17). Even though no one knows for sure how the drug works, it has been linked to nonsteroidal anti-inflammatory drugs (NSAIDs) in the past because they block cyclooxygenase (COX) processes(18,19). Similar to NSAIDs, paracetamol possesses antipyretic and analgesic properties, However, it has no peripheral anti-inflammatory effects. In the central nervous system (CNS), paracetamol can block the COX pathway; however, this effect does not extend to peripheral tissues. Additionallyit does not seem that paracetamol binds to the COX-1 or COX-2 enzymes' active sites. Rather, it applies an alternative strategy to lower COX activity Furthermore, It appears that paracetamol has no effect on the COX-1 or COX-2 enzymes' active sites. Actually, it employs a different technique to reduce COX activity (20).



Figure 2 An illustrated proposed mechanism of action Acetaminophen

According to recent research, the central nervous system's (CNS) production of the active metabolite AM404, which activates the TRPV1 receptor—a key component in pain modulation—is the primary mechanism by which paracetamol produces its analgesic action (21) (Figure 2). Acetaminophen is also thought to interact with other molecular pathways in addition to activating TRPV1. One such molecular pathway is the serotonergic system, which acetaminophen is known to stimulate. Acetaminophen also affects serotonergic pathways, which strengthens the suppression of descending pain (Figure 3). This suggests a complex mechanism including the manipulation of neurotransmitter systems (22).Given its central action that permits integration with other analgesics, the potential for creating acetaminophen compounds that improve its efficacy and safety in pain management is highlighted by the intricacy of its processes (21).



Figure 3 Emerging mechanism of action of acetaminophen involvement of metabolised of acetaminophen i.e. p-ammino-phenol which is easily cross BBB and converted in to AM404(N-(4-hydroxyphenyl) arachidonoylamide) by Fatty acid amide hydrolase (FAAH)

2.1.1. Role of corticosteroids in fever management

When it comes to treating fever, corticosteroids are quite important, especially when the illness is marked by severe inflammatory reactions. They possess antipyretic properties by inhibiting the synthesis of pro-inflammatory cytokines and reducing the overall acute phase response, which encompasses an increase in body temperature(23). Moreover, corticosteroids influence cytokine production and leukocyte activity, which reduces the development of fever (24). In the treatment of inflammatory and autoimmune illnesses when fever persists, these medications can help control fever and its associated symptoms by modifying the immune response (25). However, the risks of long-term therapy and the possibility of adverse effects must be taken into consideration when using them, especially in situations when it might be ineffective to suppress the immune response (26).

3. Types of antipyretic agents

3.1. Nonsteroidal anti-inflammatory drugs (NSAIDs)

Oral pills represent the predominant formulation of NSAIDs. The following are the dosages for the most commonly used over-the-counter NSAIDs as specified in the package insert: Ibuprofen: administer one or two 200 mg tablets every four to six hours for the duration of symptomatology. The maximum daily dosage of ibuprofen is 1200 mg. One to two 325 mg tablets every four hours, or three tablets every six hours if utilizing standard-dose aspirin is to be administered. The maximum daily dosage of aspirin is 4000 mg. One or two 220 mg tablets of naproxen sodium is to be administered every eight to twelve hours. The daily maximum for naproxen sodium is 660 mg. Topical NSAIDs include a 1.5% topical solution, 1% diclofenac sodium gel, and a 1.3% diclofenac hydroxyethyl pyrrolidine patch. The primary applications for them are in the treatment of soft tissue injuries and osteoarthritis (27,28).

3.2. Acetaminophen

Acetaminophen, which is sold under the brand names N-acetyl-p-aminophenol, APAP, paracetamol, and Tylenol®, is a popular over-the-counter pain and fever reliever that can be harmful in high doses. APAP overdose is responsible for 40–70% of cases in the UK and Europe, as well as 46% of all cases of acute liver failure (ALF) in the US(29). You can give paracetamol by mouth, orally, orally, or intravenously(30). Acetaminophen is available in several forms, including

syrup, pills, capsules, tablets, oral solution, and suspension. Acetaminophen can be administered rectally to both adult and pediatric patients in the form of a suppository. Acetaminophen may also be delivered through an intravenous infusion (31).

3.3. Dosages for adults and adolescents

The recommended dosage of acetaminophen for adults and adolescents (13 years or older) weighing 50 kg or more is 1000 mg every 6 hours or 650 mg every 4 hours. There should be a minimum of four hours between administrations, and a single dose should not exceed 1000 mg. The highest recommended daily dosage of acetaminophen is 4000 mg.

Adults and teens (13 years or older) who weigh less than 50 kg should take 12.5 mg/kg of acetaminophen every 4 hours or 15 mg/kg every 6 hours. One dose Acetaminophen should be taken in doses of 1000 mg every 6 hours or 650 mg every 4 hours for adults and teens (13 years or older) who weigh 50 kg or more. The dosage must not surpass 15 mg/kg, with a minimum interval of 4 hours between administrations. The most paracetamol that a person can take in a day is 3750 mg, or 75 mg/kg. Kids between the ages of 2 and 12 should take 12.5 mg/kg every 4 hours or 15 mg/kg every 6 hours. A person can only take 75 mg/kg of acetaminophen per day, and 15 mg/kg can be given all at once.

Neonates: Premature infants delivered at 32 weeks gestation or less should not take more than 50 mg/kg of paracetamol every day. This is also true for babies younger than 28 days. It is suggested that these babies take 12.5 mg/kg every 6 hours.

Infants: The recommended dosage for infants aged 29 days to 2 years is 15 mg/kg every 6 hours, with a maximum daily limit of 60 mg/kg of paracetamol. With a usual daily limit of 4 g, the American Geriatric Society suggests a paracetamol dosage of 325 to 500 mg every 4 hours or 500 to 1000 mg every 6 hours for older individuals. For people who have a history of alcohol abuse or hepatic impairment, a 50% to 75% reduction in the maximum dosage is recommended(32).

Table 1 Pharmacological profile of important antinociceptives and antipyretics

S. No.	Drug	Minimum dose in adults	Maximum Dose	Half life	Contraindication	Chemical name, other name
1	Acetaminophen	500–1000 mg.	4,000 mg daily limit for adults	2 to 4 hour	Acetaminophen is contraindicated in patients with severe hepatic impairment or active liver disease	Tylenol, N-acetyl-p-amino-phenol, paracetamol
2	Ibuprofen	200-400 mg	3200 mg	The serum half-life of ibuprofen is 1.2-2 hours.	ibuprofen should be used with caution in patients over 65 or with high blood pressure	*2-(4-isobutylphenyl) propionic acid*
3	Aspirin	150 to 300 mcg/mL	Greater than 300 mcg/mL	less than 30 minutes	allergy, gastrointestinal bleeding, stomach ulcers,	Salicylate, 2-Acetoxybenzoic acid
4	Naloxone	0.4-2 mg	10 mg	The mean serum half-life naloxone is 30 to 81 minutes,	hypersenstivity	N-allylnoroxymorphone
5	warfarin	2-5 mg	Greater than 10 mg	40 hours	Preganancy,hypersenstivity,several liver deases	4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one

3.4. Comparative effectiveness of antipyretics

Many research have examined the effectiveness of different antipyretics, with acetaminophen and ibuprofen being the main subjects of comparison. Research indicates that acetaminophen and ibuprofen are both useful in lowering fever, yet in some situations, ibuprofen may be more helpful. In instance, a meta-analysis showed that, especially in paediatric populations, ibuprofen consistently produced lower temperatures throughout the first 24 hours of treatment when compared to paracetamol(33). According to some research, combination therapy involving both drugs does not considerably improve fever reduction when compared to monotherapy, indicating that single-agent therapy may frequently be adequate (34).

3.4.1. Efficacy among different patient populations

Antipyretics' effectiveness frequently differs throughout patient demographics, including adults, children, and the elderly. Acetaminophen and ibuprofen are generally well tolerated in children, according to research; however, dosage changes based on age and weight are necessary(34). The same medications work well in adults; however, comorbidities and polypharmacy in older patients may cause changes in pharmacodynamics and pharmacokinetics that could affect efficacy and safety profiles(35). For example, ibuprofen and acetaminophen can both be taken safely in older persons, although the risk of gastrointestinal side effects may require close monitoring. Acetaminophen is still recommended in younger populations due to its safety profile (36).

3.4.2. Special considerations for antipyretic use

The selection of antipyretics may be influenced by certain clinical circumstances and situations. Because of its connection with gastric irritation and renal dysfunction, Patients with a history of gastrointestinal problems or chronic kidney disease are frequently recommended to take acetaminophen(36). Furthermore, because ibuprofen may raise the risk of soft tissue infections in children who are feverish and also have other diseases like chickenpox, its use may be advised with caution(37). Likewise, although combination therapy may appear advantageous in controlling elevated fever, data suggests that it does not substantially enhance results, highlighting the significance of prudent antipyretic selection predicated on unique patient circumstances (34,36).

3.4.3. Special considerations for antinociceptive use

Considerations must be made while using antinociceptive drugs to maximize efficacy and minimize hazards. These drugs can produce drowsiness, gastrointestinal issues, dependence, and tolerance, therefore side effects and drug interactions must be monitored. Starting doses should be low and titrated up based on patient response and tolerance to ensure safety and effectiveness and reduce problems. Age, comorbidities, and concurrent drugs must be considered when tailoring antinociceptive therapy. The elderly and those with renal or hepatic impairment may need altered doses to avoid toxicity. Regular follow-up helps healthcare practitioners and patients discuss medication adherence and concerns by monitoring therapeutic response and managing side effects quickly (38).

3.4.4. Safety and side effects of NSAIDs

Ibuprofen is generally well-tolerated and belongs to the nonsteroidal anti-inflammatory drugs (NSAID) class. Although it has a generally good safety profile, it can lead to gastrointestinal problems such as diarrhoea, vomiting, and nausea. Furthermore, it should not be administered to people who have certain medical disorders, such as ongoing gastrointestinal bleeding(39). Because they also inhibit prostaglandin synthase, NSAIDs are used to treat acute gout pain by inhibiting urate crystal phagocytosis(40). The need for vigilance while controlling dosage and being aware of contraindications highlights the variations in these antipyretics' safety profiles(41). In light of these variances, medical practitioners must assess each patient's unique needs while prescribing antipyretics in order to reduce risks and successfully manage symptoms(42). Thus, even if NSAIDs are useful in treating pain, medical professionals should prioritize risk assessment and monitoring, especially for patients who have known gastrointestinal or renal vulnerabilities, in order to minimize these side effects(43). The renal system, heart, liver, haematologic system, and gastrointestinal mucosa are only a few of the well-known adverse effects of NSAIDs. The inhibition of COX-1 probably causes negative consequences in the stomach because it stops prostaglandins from being synthesized, which protects the gastric mucosa. A patient is more likely to suffer injury if they have a history of peptic ulcers. The utilization of COX-2 selective NSAIDs presents a reduced danger since they specifically target COX-1.(44) COX-1 and COX-2 increase the manufacture of prostaglandins, which are essential for renal hemodynamics, causing adverse consequences on the kidneys. Inhibiting prostaglandin synthesis is not a serious concern in persons with normal renal function. However ,among those who suffer from renal impairment, using NSAIDs to reduce prostaglandin production can cause problems. Among the potential outcomes include acute renal failure, fluid and electrolyte imbalances, renal papillary necrosis, and nephrotic syndrome/interstitial nephritis (45). The use of NSAIDs may raise the risk of atrial fibrillation and other

cardiovascular problem, myocardial infarction, and thromboembolism. Diclofenac appears to be the NSAID most strongly associated with an increase in adverse cardiovascular events(46). Hepatic side effects are less prevalent; hospitalization for liver-related causes is exceedingly rare; and the risk of NSAID-associated hepatotoxicity (increased aminotransferase levels) is not particularly high. Diclofenac is more prone than other NSAIDs to have hepatotoxic adverse effects(47). The antiplatelet action of nonselective NSAIDs increases the likelihood of hematologic adverse effects. This antiplatelet impact is problematic primarily in individuals who have a history of stomach ulcers, conditions that impair platelet function (such as von Willebrand disease, thrombocytopenia, hemophilia, etc.), or in specific perioperative contexts(48). Minor side effects encompass aspirin-exacerbated respiratory disease and anaphylactoid reactions affecting the integumentary and respiratory systems, including urticaria(49,50). The principal issue of NSAID consumption is the negative consequences especially gastrointestinal complications, which include issues in the lower and upper gastrointestinal tracts, peptic ulcers, and prothrombotic effects(51). Sedation, vertigo, nausea, vomiting, constipation, physical dependency, tolerance, and respiratory depression are among the most common adverse effects of opioid medication(52). Despite the fact that both medications have documented adverse effects, opioids and non-steroidal anti-inflammatory drugs (NSAIDs) are the primary medications used to treat pain and inflammation. Opioid analgesics are the most effective and frequently used medications for individuals experiencing malignant and non-malignant pain that is refractory, and they are used to treat moderate to severe acute pain. Opioids include many compounds that function as agonists of opioid receptors, triggering symptoms typical of morphine(53).

3.5. Safety and side effects of acetaminophen

Although paracetamol is often thought of as a safe drug, there are a number of serious hazards associated with it, especially with relation to liver toxicity and the possibility of overdosing. Due to accidental overdosesIt is the primary cause of acute hepatic failure in the United States. Resulting in thousands of emergency room visits and hospital admissions yearly(54). There are few symptoms and no sedative effect after an acetaminophen overdose at one time. However, between 12 and 24 hours later, nausea and abdominal pain start to appear (54). Under normal conditions, the liver uses a variety of routes to handle acetaminophen, although glucuronidation and sulfation are the main ones. On the other hand, in overdose scenarios, these pathways become saturated and N-acetyl-p-benzoquinone imine (NAPQI), An unsafe metabolite, is formed. NAPQI can bind to cellular macromolecules when glutathione supplies are low, causing permanent damage and hepatic necrosis(55). Because paracetamol is frequently mixed with other drugs in prescription prescriptions and many over-the-counter products, there is an increased risk of inadvertent overdose. Many people are not aware that the cumulative dosage from various sources can easily surpass the adult guideline limits of 4 grammes per day(53). Doses as low as 7.5 g/day to 10 g/day can cause toxicity, and N-acetylcysteine is frequently needed for immediate medical attention in cases of severe liver damage(55). Healthcare providers and patients alike must be aware of the dangers of paracetamol, particularly the possibility of severe hepatotoxicity and overdosage. To avoid negative effects related to its use, proper dose information is required(54) Recommend to patients to take no more than 4 grammes of paracetamol per day in total.Acetaminophen use has been linked to acute liver failure cases that end in death and necessitate liver transplantation.Inform patients that it's crucial to read the labels on all over-the-counter and prescription medications to make sure they aren't taking Several products that include paracetamol.Recommend to patients not to consume alcohol when taking drugs that contain paracetamol. When paracetamol is used, there have been sporadic reports of anaphylaxis and other hypersensitivity responses. Tell patients to get help as soon as possible if they experience any of the following symptoms: rash, itching, breathing problems, swelling in the face, mouth, or throat, or taking more paracetamol than is advised(56).

3.5.1. Medication-Drug Reactions

Warfarin: In patients on warfarin, an extended oral paracetamol dose (4000 mg/d) has been linked to an increased international normalized ratio (INR). Owing to the paucity of studies assessing the short-term use of acetaminophen in conjunction with oral anticoagulants, it could be prudent in these circumstances to check INR more often. Alcohol: Chronic alcohol consumption increases the likelihood of paracetamol toxicity by impairing NAPQI detoxification, depleting hepatic glutathione (GSH) levels, and activating CYP2E1. It may also induce hepatocyte membrane disruptions, elevate oxidation, diminish glucuronidation, and reduce biliary excretion(57).

3.5.2. Comparative safety of antipyretics, antinociceptive

The comparative safety profiles of aspirin, ibuprofen, and acetaminophen show that although all three are useful in treating fever and pain, they each have different safety concerns. The high safety profile of paracetamol is widely acknowledged, provided that it is delivered in suitable therapeutic amounts. But if overdosed, there is a considerable danger of abrupt liver failure and severe allergic reactions, which emphasises the significance of following prescribed dosages(58). The relative safety of antinociceptive drugs is essential in pain therapy, as opioids such as morphine offer significant analgesic effects but pose dangers including respiratory depression and potential for misuse. Kappa-opioid

agonists, like U50488-H, provide excellent analgesia with less gastrointestinal adverse effects, rendering them appropriate for patients susceptible to opioid dependence. Patient-specific attributes, prolonged effects such as tolerance, and continuous safety evaluations are essential for enhancing pain management approaches and safeguarding patient welfare(59).

3.6. Antipyretic, antinociceptive usage clinical guidelines

According to recent clinical guidelines, parents should use antipyretics carefully and cautiously when giving them to their children. This is because many parents worry that their child will not keep a "normal" temperature, especially in cases when there is just a slight fever(60). Addressing the physiological justification for antipyresis, which implies that the advantages may not always exceed the hazards, the American College of Physicians has emphasised the significance of evidence-based assessments about the safety and efficacy of antipyretics in adult populations(61). The benefit-harm equilibrium of antipyretic administration in older patients is frequently ambiguous due to their typically diminished fever response; this underscores the necessity for meticulous evaluation when chronic conditions initiate or exacerbate, alongside vigilant oversight of antipyretic usage during infections.(62) Importantly for physicians, research also shows that antipyretics do not substantially affect the immunological response to immunisations, even though they may reduce fever in post-vaccination situations(63). These Guidelines underscore the essential information, abilities, and activities that form the core elements of proficient management of chronic pain and related concerns. The Guidelines acknowledge that managing chronic pain is part of a larger field of health care that includes quality of life and psychosocial performance. These guidelines are for people who have ongoing neuropathic, somatic (like myofascial), or visceral pain syndromes that are not cancer. Patients with acute pain from an injury or surgery, cancer-related pain, pain from degenerative major joint diseases, headache syndromes (such as migraine and cluster headaches), temporomandibular joint syndrome, or trigeminal and other neuralgias affecting the head or face are not covered by the Guidelines. The Guidelines don't cover young patients and don't cover giving drugs through an IV or surgery, except for nerve stimulators and drug delivery devices that are implanted into the spinal cord (64).

3.7. Recommended practices for antipyretic use

The prevailing clinical opinion suggests that antipyretics ought to be administered mainly to improve comfort rather than just to lower fever in patients. When a child's fever reaches 101°F (38.3°C) or when discomfort is noticeable, the American Academy of Pediatrics advises starting treatment. It should be noted that fever in children is usually not harmful and can even act as a defense against diseases. Studies also show that antipyretic medication administration does not significantly reduce the incidence of febrile seizures or decrease morbidity or mortality associated with high fevers. In addition, combination therapy—which combines acetaminophen and ibuprofen—has grown in popularity. Nevertheless, data indicates that this strategy does not reduce fever as well and can result in dosage errors if carers do not understand it effectively. To guarantee the safe and efficient administration of antipyretics, it is imperative to educate carers about appropriate dosages, dosing intervals, and the cause of fever (65).

3.8. Recent advances and future directions

Even though paracetamol has been used for a long time and has a good reputation for safety, it needs to be carefully monitored by a multidisciplinary team of professionals who know about all of the patient's other medications. According to a recent study, hospitalizations and the proportion of cases of acute liver failure caused by acetaminophen and opioid poisoning significantly decreased following the FDA's 2011 rule, which limits the amount of acetaminophen in pills when opioids are present to 325 mg. These results demonstrate the influence of regulatory actions on adverse drug-related occurrences and patient safety(66). Current research has revealed that paracetamol can be used safely in patients with chronic kidney disease, (67) that it is significantly effective for pain after arthroplasty, (68)that it is less effective than ibuprofen for pain after laminectomy, (69) that paracetamol in the emergency department (70) has opioid-sparing effects, that paracetamol is not recommended in cases of lumbar spinal stenosis with neurogenic claudication,(71) and that paracetamol is recommended for postcesarean pain and migraine(72,73). Paracetamol is one of the most well-known drugs, both with and without a prescription, and is likely to remain so. As the world ages, the number of unpleasant and incapacitating conditions increases. With its outstanding safety record, paracetamol is widely recommended for persons of all ages, but notably the elderly. Although it is unknown at doses of up to 4 g/day, liver damage is a concern. Guidelines recommend paracetamol for the treatment of a number of acute and chronic pain disorders, despite the fact that it has been subjected to extensive testing for safety and efficacy(73). A recent Cochrane review examined the efficacy of preventive antiepileptics and antipyretics in preventing recurrent febrile seizures. The review included 30 studies that analyzed a total of 4256 children aged 6 months to 7 years(74). Stem cell treatment exhibits significant potential in treating neuropathic and nociceptive pain by differentiating stem cells into various cell types, promoting tissue regeneration, and altering pain feelings. It effectively addresses conditions such as diabetic neuropathy and spinal cord injuries by utilizing human mesenchymal stem cells (MSCs) for their regenerative

properties and cytokine synthesis. Clinical trials demonstrate the ability of MSCs to alleviate pain; nevertheless, the choice between allogeneic and autologous sources is essential. However, challenges remain about optimal dosage, safety, and long-term effects, necessitating additional study and clinical trials to validate these findings. Nanomedicine makes use of nanoparticles to distribute drugs precisely, increasing the potency of poorly soluble drugs while lowering their toxicity. Current studies highlight the use of an esketamine nanoparticle-hydrogel delivery system (NHDS), which significantly improves analgesic efficacy in models of neuropathic pain. Zinc oxide nanoparticles (nZnO) are under examination for their analgesic properties by modulating NMDA receptor activation and augmenting opioid effects. Despite the considerable promise of nanoparticles in pain management and several chronic health conditions, further investigation is necessary to definitively establish their clinical effectiveness (75).

4. Conclusion

The field of antipyretic and antinociceptive treatments is advancing, with notable progress in comprehending their mechanisms, safety profiles, and clinical uses. Antipyretics, chiefly non-steroidal anti-inflammatory drugs (NSAIDs) and paracetamol, are essential in the management of fever and related discomfort in patients, highlighting the necessity of precise doses to enhance efficacy and reduce hazards. Future therapies will likely concentrate on improving the safety and efficacy of antipyretic drugs, especially in at-risk groups such as children and the elderly. Moreover, the continuous investigation into innovative delivery systems and the examination of alternative chemicals have the potential for more precise therapies that can enhance pain management and fever alleviation strategies. Meticulous evaluation of unique patient requirements, pharmacodynamics, and possible drug interactions will be crucial in customizing antipyretic and antinociceptive therapies to achieve the best therapeutic results. A multidisciplinary approach will be essential for effectively managing fever and discomfort, enhancing patient care, and promoting innovative pharmacotherapeutic options.

Compliance with ethical standards

Disclosure of conflict of interest

There is not any conflict of interest among the authors as it is team work.

References

[1] Plaisance KI, Mackowiak PA. Antipyretic therapy: physiologic rationale, diagnostic implications, and clinical consequences. Arch Intern Med. 2000;160(4):449–56.

[2] Kataria S, Patel U, Yabut K, Patel J, Patel R, Patel S, et al. Recent Advances in Management of Neuropathic, Nociceptive, and Chronic Pain: A Narrative Review with Focus on Nanomedicine, Gene Therapy, Stem Cell Therapy, and Newer Therapeutic Options. Curr Pain Headache Rep. 2024;1–13.

[3] Woolf CJ. Pain: moving from symptom control toward mechanism-specific pharmacologic management. Ann Intern Med. 2004;140(6):441–51.

[4] Prajitha N, Athira SS, Mohanan P V. Comprehensive biology of antipyretic pathways. Cytokine. 2019;116:120–7.

[5] McCARTHY PL. 8 Down-regulation of cytokine action. Baillieres Clin Haematol. 1994;7(1):153–77.

[6] Prajitha N, Athira SS, Mohanan P V. Comprehensive biology of antipyretic pathways. Cytokine. 2019;116:120–7.

[7] Opal SM, DePalo VA. Anti-inflammatory cytokines. Chest. 2000;117(4):1162–72.

[8] Mackowiak PA. Brief history of antipyretic therapy. Clinical infectious diseases. 2000;31(Supplement_5):S154–6.

[9] Sullivan JE, Farrar HC, Therapeutics S on CP and, Drugs C on. Fever and antipyretic use in children. Pediatrics. 2011;127(3):e20103852.

[10] Aronoff DM, Neilson EG. Antipyretics: mechanisms of action and clinical use in fever suppression. Am J Med. 2001;111(4):304–15.

[11] Ghlichloo I, Gerriets V. Nonsteroidal anti-inflammatory drugs (NSAIDs). 2019;

[12] Cronstein BN, Sunkureddi P. Mechanistic aspects of inflammation and clinical management of inflammation in acute gouty arthritis. JCR: Journal of Clinical Rheumatology. 2013;19(1):19–29.

[13] Koeberle A, Werz O. Inhibitors of the microsomal prostaglandin E2 synthase-1 as alternative to non steroidal anti-inflammatory drugs (NSAIDs)-a critical review. Curr Med Chem. 2009;16(32):4274–96.

[14] Nabulsi M. Is combining or alternating antipyretic therapy more beneficial than monotherapy for febrile children? BMJ. 2009;339.

[15] Coceani F, Bishai I, Lees J, Sirko S. Prostaglandin E2 and fever: a continuing debate. Yale J Biol Med. 1986;59(2):169.

[16] Rainsford KD. Ibuprofen: pharmacology, efficacy and safety. Inflammopharmacology. 2009;17:275–342.

[17] Bunchorntavakul C, Reddy KR. Acetaminophen-related hepatotoxicity. Clin Liver Dis. 2013;17(4):587–607.

[18] Ghanem CI, Pérez MJ, Manautou JE, Mottino AD. Acetaminophen from liver to brain: New insights into drug pharmacological action and toxicity. Pharmacol Res. 2016;109:119–31.

[19] Smith HS. Potential analgesic mechanisms of acetaminophen. Pain Physician. 2009;12(1):269.

[20] Chandrasekharan N V, Dai H, Roos KLT, Evanson NK, Tomsik J, Elton TS, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proceedings of the National Academy of Sciences. 2002;99(21):13926–31.

[21] Mallet C, Desmeules J, Pegahi R, Eschalier A. An updated review on the metabolite (AM404)-mediated central mechanism of action of paracetamol (acetaminophen): experimental evidence and potential clinical impact. J Pain Res. 2023;1081–94.

[22] Anderson BJ. Paracetamol (Acetaminophen): mechanisms of action. Pediatric Anesthesia. 2008;18(10):915–21.

[23] Coelho MM, Luheshi G, Hopkins SJ, Pela IR, Rothwell NJ. Multiple mechanisms mediate antipyretic action of glucocorticoids. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. 1995;269(3):R527–35.

[24] Schwiebert LA, Beck LA, Stellato C, Bickel CA, Bochner BS, Schleimer RP. Glucocorticosteroid inhibition of cytokine production: relevance to antiallergic actions. Journal of Allergy and Clinical Immunology. 1996;97(1):143–52.

[25] Shuto H, Komiya K, Usagawa Y, Yamasue M, Fushimi K, Hiramatsu K, et al. Corticosteroid Therapy for Patients With Severe Fever With Thrombocytopenia Syndrome: A Nationwide Propensity Score–Matched Study in Japan. In: Open Forum Infectious Diseases. Oxford University Press US; 2023. p. ofad418.

[26] Lee ZY, Tam JKC, Tran T. Corticosteroid use in respiratory viral infections—friend or foe? Curr Opin Physiol. 2021;22:100450.

[27] Barkin RL. Topical nonsteroidal anti-inflammatory drugs: the importance of drug, delivery, and therapeutic outcome. Am J Ther. 2015;22(5):388–407.

[28] Ghlichloo I, Gerriets V. Nonsteroidal anti-inflammatory drugs (NSAIDs). 2019;

[29] Bernal W, Auzinger G, Dhawan A, Wendon J. Acute liver failure. The Lancet. 2010;376(9736):190–201.

[30] Bannwarth B, Pehourcq F. Pharmacological rationale for the clinical use of paracetamol: pharmacokinetic and pharmacodynamic issues. Drugs. 2003;63:5–13.

[31] Gerriets V, Anderson J, Patel P, Nappe TM. Acetaminophen. In: StatPearls [internet]. StatPearls Publishing; 2024.

[32] Persons O. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc. 2009;57(8):1331–46.

[33] Tan E, Braithwaite I, McKinlay CJD, Dalziel SR. Comparison of acetaminophen (paracetamol) with ibuprofen for treatment of fever or pain in children younger than 2 years: a systematic review and meta-analysis. JAMA Netw Open. 2020;3(10):e2022398–e2022398.

[34] Hoover L. AAP reports on the use of antipyretics for fever in children. Am Fam Physician. 2012;85(5):518–9.

[35] Mehmood KT, Al-Baldawi S, Salazar GZ, Zúñiga D, Balasubramanian S. Antipyretic Use in Noncritically Ill Patients With Fever: A Review. Cureus. 2024;16(1).

[36] Park YR, Kim H, Park JA, Ahn SH, Chang S, Shin JW, et al. Comparative analysis of single and combined antipyretics using patient-generated health data: retrospective observational study. JMIR Mhealth Uhealth. 2021;9(5):e21668.

[37] Esch T, Kream RM, Stefano GB. Emerging regulatory roles of opioid peptides, endogenous morphine, and opioid receptor subtypes in immunomodulatory processes: Metabolic, behavioral, and evolutionary perspectives. Immunol Lett. 2020;227:28–33.

[38] Kanabar DJ. A clinical and safety review of paracetamol and ibuprofen in children. Inflammopharmacology. 2017;25(1):1–9.

[39] Cronstein BN, Sunkureddi P. Mechanistic aspects of inflammation and clinical management of inflammation in acute gouty arthritis. JCR: Journal of Clinical Rheumatology. 2013;19(1):19–29.

[40] Paul IM, Walson PD. Acetaminophen and ibuprofen in the treatment of pediatric fever: a narrative review. Curr Med Res Opin. 2021;37(8):1363–75.

[41] Mehmood KT, Al-Baldawi S, Salazar GZ, Zúñiga D, Balasubramanian S. Antipyretic Use in Noncritically Ill Patients With Fever: A Review. Cureus. 2024;16(1).

[42] Saad J, Mathew D. Nonsteroidal anti-inflammatory drugs toxicity. 2018;

[43] Barkin RL. Topical nonsteroidal anti-inflammatory drugs: the importance of drug, delivery, and therapeutic outcome. Am J Ther. 2015;22(5):388–407.

[44] Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med. 1999;106(5):13S-24S.

[45] Harirforoosh S, Asghar W, Jamali F. Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications. Journal of Pharmacy & Pharmaceutical Sciences. 2013;16(5):821–47.

[46] Sriuttha P, Sirichanchuen B, Permsuwan U. Hepatotoxicity of nonsteroidal anti-inflammatory drugs: A systematic review of randomized controlled trials. Int J Hepatol. 2018;2018(1):5253623.

[47] Schafer AI. Effects of nonsteroidal anti-inflammatory therapy on platelets. Am J Med. 1999;106(5):25S-36S.

[48] Ghlichloo I, Gerriets V. Nonsteroidal anti-inflammatory drugs (NSAIDs). 2019;

[49] Szczeklik A. Adverse reactions to aspirin and nonsteroidal anti-inflammatory drugs. Ann Allergy. 1987;59(5 Pt 2):113–8.

[50] Benyamin R, Trescot AM, Datta S, Buenaventura RM, Adlaka R, Sehgal N, et al. Opioid complications and side effects. Pain Physician. 2008;11(2S):S105.

[51] Steinmeyer J. Pharmacological basis for the therapy of pain and inflammation with nonsteroidal anti-inflammatory drugs. Arthritis Res Ther. 2000;2:1–7.

[52] Albalawi MA, Albalawi SA, Albalawi THS, Almuhawwis KS, Alswilem AM, Aldakhil MF, et al. Evaluation of recent updates regarding acetaminophen-induced acute liver failure. Arch Pharm Pract. 2019;10(3–2019):56–60.

[53] Lee WM. Acetaminophen (APAP) hepatotoxicity—isn't it time for APAP to go away? J Hepatol. 2017;67(6):1324–31.

[54] Ambizas EM. Acetaminophen toxicity: what pharmacists need to know. US Pharm. 2014;3:19.

[55] Nourjah P, Ahmad SR, Karwoski C, Willy M. Estimates of acetaminophen (Paracetomal)-associated overdoses in the United States. Pharmacoepidemiol Drug Saf. 2006;15(6):398–405.

[56] Caparrotta TM, Antoine DJ, Dear JW. Are some people at increased risk of paracetamol-induced liver injury? A critical review of the literature. Eur J Clin Pharmacol. 2018;74:147–60.

[57] Gallantine EL, Meert TF. Antinociceptive and Adverse Effects of μ-and κ-Opioid Receptor Agonists: A Comparison of Morphine and U50488-H. Basic Clin Pharmacol Toxicol. 2008;103(5):419–27.

[58] Ambizas EM. Acetaminophen toxicity: what pharmacists need to know. US Pharm. 2014;3:19.

[59] Sullivan JE, Farrar HC, Therapeutics S on CP and, Drugs C on. Fever and antipyretic use in children. Pediatrics. 2011;127(3):e20103852.

[60] Mahesh S, van der Werf E, Mallappa M, Vithoulkas G, Lai NM. Long-term health effects of antipyretic drug use in the ageing population: protocol for a systematic review. F1000Res. 2020;9.

[61] Mehmood KT, Al-Baldawi S, Salazar GZ, Zúñiga D, Balasubramanian S. Antipyretic Use in Noncritically Ill Patients With Fever: A Review. Cureus. 2024;16(1).

[62] Plaisance KI, Mackowiak PA. Antipyretic therapy: physiologic rationale, diagnostic implications, and clinical consequences. Arch Intern Med. 2000;160(4):449–56.

[63] Management AS of ATF on CP. Practice guidelines for chronic pain management: an updated report by the American Society of Anesthesiologists Task Force on Chronic Pain Management and the American Society of Regional Anesthesia and Pain Medicine. Anesthesiology. 2010;112(4):810–33.

[64] Hoover L. AAP reports on the use of antipyretics for fever in children. Am Fam Physician. 2012;85(5):518–9.

[65] Orandi BJ, McLeod MC, MacLennan PA, Lee WM, Fontana RJ, Karvellas CJ, et al. Association of FDA mandate limiting acetaminophen (paracetamol) in prescription combination opioid products and subsequent hospitalizations and acute liver failure. JAMA. 2023;329(9):735–44.

[66] Dolati S, Tarighat F, Pashazadeh F, Shahsavarinia K, Gholipouri S, Soleimanpour H. The role of opioids in pain management in elderly patients with chronic kidney disease: a review article. Anesth Pain Med. 2020;10(5).

[67] Anger M, Valovska T, Beloeil H, Lirk P, Joshi GP, Van de Velde M, et al. PROSPECT guideline for total hip arthroplasty: a systematic review and procedure-specific postoperative pain management recommendations. Anaesthesia. 2021;76(8):1082–97.

[68] Akbas S, Ozkan AS, Durak MA, Yologlu S. Efficacy of intravenous paracetamol and ibuprofen on postoperative pain and morphine consumption in lumbar disc surgery: prospective, randomized, double-blind, placebo-controlled clinical trial. Neurochirurgie. 2021;67(6):533–9.

[69] Ramdin C, Yu C, Colorado J, Nelson L. The impact of adherence to a guideline for minimizing opioid use for treatment of pain in an urban emergency department. Am J Emerg Med. 2021;49:104–9.

[70] Bussières A, Cancelliere C, Ammendolia C, Comer CM, Al Zoubi F, Châtillon CE, et al. Non-surgical interventions for lumbar spinal stenosis leading to neurogenic claudication: a clinical practice guideline. J Pain. 2021;22(9):1015–39.

[71] Wong I, St John-Green C, Walker SM. Opioid-sparing effects of perioperative paracetamol and nonsteroidal anti-inflammatory drugs (NSAID s) in children. Pediatric Anesthesia. 2013;23(6):475–95.

[72] Robbins MS. Diagnosis and management of headache: a review. JAMA. 2021;325(18):1874–85.

[73] Freo U, Ruocco C, Valerio A, Scagnol I, Nisoli E. Paracetamol: a review of guideline recommendations. J Clin Med. 2021;10(15):3420.

[74] Offringa M, Newton R, Nevitt SJ, Vraka K. Prophylactic drug management for febrile seizures in children. Cochrane Database of Systematic Reviews. 2021;(6).

[75] Meissner K, Henthorn TK. How relevant is stereoselectivity to the side-effects of ketamine? Br J Anaesth. 2021;127(1):1–2